scientific presentations

MGTA-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 study
ASH Annual Meeting Poster, December 2021

Phase 2 study of MGTA-145 + Plerixafor for Rapid and Reliable Hematopoietic Stem Cell (HSC) Mobilization for Autologous Stem Cell Transplant in Multiple Myeloma
ASCO 2021, June 2021

Phase 2 Study of MGTA-145 + Plerixafor for Rapid and Reliable Hematopoietic Stem Cell (HSC) Mobilization for Autologous Stem Cell Transplant in Multiple Myeloma (Abstract EP1224)
EHA Congress 2021, June 2021

MGTA-145, in Combination with Plerixafor in a Phase 1 Clinical Study, Mobilizes Large Numbers of Hematopoietic Stem Cells and a Graft with Potent Immunosuppressive Properties for Autologous and Allogeneic Transplant
EBMT 2021 Annual Meeting Presentation, March 2021

MGTA-145, in Combination with Plerixafor in a Phase 1 Clinical Study, Mobilizes Large Numbers of Hematopoietic Stem Cells and a Graft with Potent Immunosuppressive Properties for Autologous and Allogeneic Transplant (Oral Abstract, #35)
TCT Annual Meeting Presentation, February 2021

MGTA-145 / Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient in vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells (Oral Abstract, #16)
TCT Annual Meeting Presentation, February 2021

MGTA-145/Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient in vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells of CD46-Transgenic and Thalassemia Mice (Abstract #2602)
ASH Annual Meeting Poster, December 2020

MGTA-145, In Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant (Oral Abstract #184)
ASH Annual Meeting Presentation, December 2020

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of MGTA-145 Alone or in Combination with Plerixafor (Abstract #A325)
EBMT Annual Meeting Poster, Aug/Sept 2020

MGTA-145, in Combination with Plerixafor, Rapidly Mobilizes Large Numbers of HSCs in Humans That Can Be Gene Edited with CRISPR/Cas9 and Mediate Superior Engraftment to Standard-of-Care (Abstract #123)
ASGCT Annual Meeting Presentation, May 2020

MGTA-145/Plerixafor-Mediated HSC Mobilization Allows for Efficient In Vivo HSC Transduction and Stable Gene Marking in Murine Peripheral Blood Cells (Abstract #810)
ASGCT Annual Meeting Poster, May 2020

Phase 1 Clinical Study of MGTA-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ HSCs without G-CSF (Abstract #73)
TCT Annual Meeting Presentation, February 2020

Rapid and Robust Mobilization of CD34 + HSCs without G-CSF Following Administration of MGTA-145 Alone or in Combination with Plerixafor (Abstract #1961)
ASH Annual Meeting Poster, December 2019

CD117 Antibody Drug Conjugate-Based Conditioning Allows for Efficient Engraftment of Gene-Modifed CD34+ Cells in a Rhesus Gene Therapy Model
ASH Presentation, December 2021

Single Agent CD117-targeted Antibody Drug Conjugate in Combination with Lymphodepleting Antibodies Enables Allogeneic Hematopoietic Stem Cell Transplantation in Mice without Chemotherapy or Radiation
ASH Annual Meeting Poster, December 2021

A Novel Short Half-life Anti-Human CD117-Amanitin ADC Exhibits Dual HSCT Conditioning and Anti-Leukemia Activity and Extends Survival in Multiple Preclinical Models of AML
EBMT Annual Meeting Poster, March 2021

A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-life Provides Dual Conditioning and Anti-Leukemia Activity and Extends Survival Compared to Standard of Care in Multiple Pre-clinical Models of Acute Myeloid Leukemia (AML) (Oral Abstract, #53)
TCT Annual Meeting Presentation, February 2021

A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemia Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML) (Abstract #1044)
ASH Annual Meeting Poster, December 2020

A Single Dose of CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy in Nonhuman Primates (Abstract #5)
TCT Annual Meeting Presentation, February 2020

A Non-Genotoxic Anti-CD117 Antibody Drug Conjugate (ADC) Designed for Patient Conditioning Prior to Stem Cell Transplant and HSC-Based Gene Therapy Has a Broad Therapeutic Window Across Species (Abstract #44)
TCT Annual Meeting Presentation, February 2020

A Single Dose of CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy in Nonhuman Primates (Abstract #610)

Targeted CD45 Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model as a Single Agent (Poster #242)
TCT Annual Meeting Presentation, February 2021

Reversing clonal hematopoiesis and associated atherosclerotic disease by targeted antibody-drug-conjugate (ADC) conditioning and transplant (Abstract #1843)
ASH Annual Meeting Presentation, December 2020

Single Agent CD45-targeted Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model (Abstract #2330)
ASH Annual Meeting Presentation, December 2020

A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody Drug Conjugates Ameliorate Disease in Preclinical Autoimmune Disease Models and Enable Auto HSCT (Abstract #0030)
EBMT Annual Meeting Poster, Aug/Sept 2020

A CD45-targeted Antibody Drug Conjugate Enables Allogeneic Hematopoietic Stem Cell Transplantation as a Single Agent in Mice (Abstract #A174)
EBMT Annual Meeting Poster, Aug/Sept 2020

A Novel Targeted Approach to Achieve Immune System Reset: A Single Dose of Magenta CD45-Targeted Antibody Drug Conjugate Enables Autologous HSCT and Ameliorates Disease in Murine Models of Autoimmune Disease (Abstract #3208)
ASH Annual Meeting Poster, December 2019

Administration of a CD45 Antibody Drug Conjugate As a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease (Abstract #120)

Expansion with E478 Significantly Increases the Rate of CRISPR-Mediated Homology Directed Repair (HDR) and Improves Engraftment of Human Hematopoietic Stem Cells (Abstract #10)
ASGCT Annual Meeting Presentation, May 2020